COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation—A Single-Center Study

Background: The effective development of COVID-19 vaccination has mitigated its harm. Using two laboratory methods, we investigated the efficacy of the BNT162b2 mRNA and BBIBP-CorV COVID-19 vaccines on seroconversion rates in cancer patients undergoing active cancer treatment. Methods: SARS-CoV-2 va...

Descripción completa

Detalles Bibliográficos
Autores principales: Souan, Lina, Abdel-Razeq, Hikmat, Nashwan, Sura, Al Badr, Sara, Alrabi, Kamal, Sughayer, Maher A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674399/
https://www.ncbi.nlm.nih.gov/pubmed/38005991
http://dx.doi.org/10.3390/vaccines11111659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674399/
https://www.ncbi.nlm.nih.gov/pubmed/38005991
http://dx.doi.org/10.3390/vaccines11111659

Ejemplares similares